A Non-interventional Observational Post Authorization Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide (REVIEW)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms REVIEW
- Sponsors Celgene Corporation
- 05 Mar 2018 Planned End Date changed from 1 Dec 2018 to 30 Oct 2018.
- 19 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018 as per ClinicalTrials.gov record.
- 19 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.